文献速递咽喉与嗓音

喉科实践趋势:神经调节剂治疗慢性咳嗽

Practice Trends in Laryngology: Neuromodulators for Treatment of Chronic Cough.
PubMed 文献 · Laryngoscope · 2025-03-21

该研究通过匿名29项问卷调查美国执业喉科医生,评估神经调节剂治疗慢性咳嗽的实践趋势。共85名来自26个州的喉科医生回应,96.5%处方神经调节剂,加巴喷丁和阿米替林为首选一线药物,咳嗽复发时重新启用之前有效药物的门槛较低。

要点

  • 96.5%的喉科医生为慢性咳嗽处方神经调节剂,为难治性有明确病因慢性咳嗽(37.8%)和不明原因慢性咳嗽(50.6%)的首选一线治疗。
  • 最常用的神经调节剂为加巴喷丁(97.6%)、阿米替林(91.5%)和曲马多(73.2%);首选一线药物亦为加巴喷丁(45.1%)、阿米替林(39.0%)和曲马多(11.0%)。
  • 神经调节剂有效时,多数等待3-6个月再调整,然后减至最低有效止咳剂量(68.3%)或完全渐减(24.4%);失败时43.9%换用另一种神经调节剂,24.4%转为喉上神经阻滞。

核心结论

  • 喉科医生常规为不明原因和难治性慢性咳嗽处方神经调节剂,加巴喷丁和阿米替林为首选一线药物,通常滴定至最大效应并平衡副作用,咳嗽复发时重新启用之前有效神经调节剂的门槛较低。

研究设计与样本

  • 匿名29项问卷调查,包含多选题、Likert量表和自由文本,以电子方式分发给美国执业喉科医生。

主要发现

  • 85名来自26个州的喉科医生回应;96.5%为慢性咳嗽处方神经调节剂,且为refractory explained chronic cough(37.8%)和unexplained chronic cough(50.6%)的首选一线治疗。
  • 最常用药物为加巴喷丁(97.6%)、阿米替林(91.5%)、曲马多(73.2%);首选一线药物为加巴喷丁(45.1%)、阿米替林(39.0%)、曲马多(11.0%)。
  • 神经调节剂有效时,多数等待3-6个月再调整,然后减至最低可能止咳剂量(68.3%)或完全渐减(24.4%)。
  • 神经调节剂失败时:43.9%渐减并换用另一种神经调节剂;24.4%转为喉上神经(SLN)阻滞。
  • 有效神经调节剂渐减后咳嗽几乎立即复发时,多数会重新启用(97.6%可能或极可能);未来咳嗽复发时,典型做法包括以先前耐受的有效剂量重新启用同一有效神经调节剂(40.5%)或重新滴定至所需的新有效剂量(51.9%)。

临床怎么用

  • 喉科医生常规为不明原因和难治性慢性咳嗽处方神经调节剂,加巴喷丁和阿米替林为首选一线药物,通常滴定至最大效应并平衡副作用。
  • 咳嗽复发时重新启用之前有效神经调节剂的门槛较低。
  • 若初始神经调节剂无效,考虑换用另一种神经调节剂或喉上神经阻滞。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Assess practice trends among laryngologists within the United States surrounding neuromodulator use for chronic cough treatment. METHODS: Anonymous 29-item survey comprised of a mixture of multiple choice, Likert scale, and free-text answers was electronically distributed to practicing laryngologists in the United States. RESULTS: Eighty-five laryngologists from 26 states responded. The majority (96.5%) prescribe neuromodulators for chronic cough and are the preferred first-line treatment for refractory explained chronic cough (37.8%) and unexplained chronic cough (50.6%). Gabapentin (97.6%), amitriptyline (91.5%), and tramadol (73.2%) are the most used. The preferred first-line drugs were also gabapentin (45.1%), amitriptyline (39.0%), and tramadol (11.0%). Most wait 3-6 months before making changes when a neuromodulator is successful, then wean to the lowest possible cough-controlling dose (68.3%) or taper off completely (24.4%). When a neuromodulator fails: 43.9% wean and try another neuromodulator; others shift to a superior laryngeal nerve (SLN) block (24.4%). When cough recurs almost immediately after weaning an effective neuromodulator, most will re-initiate it again (97.6% likely or highly likely). If the cough recurs in the future, typical practice includes reinitiating the same prior effective neuromodulator at its previously tolerated effective dose (40.5%) or re-titrating to the new effective dose needed (51.9%). CONCLUSIONS: Laryngologists routinely prescribe neuromodulators for unexplained and refractory chronic cough. Gabapentin and amitriptyline are the preferred first-line agents, generally titrated to maximal effect, balancing against side effects. A low threshold to reinitiate previously effective neuromodulators exists when cough recurs. If an initial neuromodulator is unsuccessful, either a different neuromodulator or a SLN block is considered.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Dwyer CD, Johns MM, Shin JJ, et al. Practice Trends in Laryngology: Neuromodulators for Treatment of Chronic Cough. Laryngoscope. 2025. PMID: 40116593. doi:10.1002/lary.32109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。